Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
Clark, Richard E, Basabrain, Ammar A, Austin, Gemma M, Holcroft, Alison K, Loaiza, Sandra, Apperley, Jane F, Law, Christopher, Scott, Laura, Parry, Alexandra D, Bonnett, Laura, Lucas, Claire M
Published in Cancers (29.04.2021)
Published in Cancers (29.04.2021)
Get full text
Journal Article
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K., Burnett, Alan K., Clark, Richard E.
Published in Blood advances (08.05.2018)
Published in Blood advances (08.05.2018)
Get full text
Journal Article
PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia
Hills, Robert K, Lucas, Claire M, Scott, Laura J, Carmell, Natasha, Holcroft, Alison K, Clark, Richard E.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article